SOPHARMA AD hereby informs that from 20 November 2014 up to and including 26 November 2014 the Company bought 1 211 own shares representing 0.0009% of the share capital of the Company, to the total value of 4 479.49 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 110 663, representing 3.87% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 20 June 2013 up to and including 26 June 2013 the Company bought 11210 own shares representing 0.008% of the share capital of the Company, to the total value of BGN 35719.22 on the Bulgarian Stock Exchange. The average price per share was BGN 3.19.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4406582, representing 3.34% of the share capital of the Company.

SOPHARMA AD hereby informs that from 27 November 2014 up to and including 3 December 2014 the Company bought 2 180 own shares representing 0.0017% of the share capital of the Company, to the total value of 8 285.7 BGN on the Bulgarian Stock Exchange, the average price per share was 3.80 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 112 843, representing 3.87% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 27 June 2013 up to and including 3 July 2013 the Company bought 14186 own shares representing 0.011% of the share capital of the Company, to the total value of BGN 44612.06 on the Bulgarian Stock Exchange. The average price per share was BGN 3.14.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4420768, representing 3.35% of the share capital of the Company.

Sopharma AD notifies that for November 2014 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2013, including 4% increase of domestic sales and 11% decrease of export sales. During the past eleven months Sopharma AD recorded a decrease of sales revenues of 4%, including 4% increase of domestic sales and 7% decrease of export sales compared to the same period of 2013.

Sopharma AD (the “Company”) announces that on 18 June 2013 the Company bought 4 039 from the capital increase of Lavena AD. After this transaction, the share of Sopharma AD in the capital of Lavena AD increased to 5.18%.

SOPHARMA AD hereby informs that from 4 December 2014 up to and including 10 December 2014 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 796 BGN on the Bulgarian Stock Exchange, the average price per share was 3.98 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 113 043, representing 3.87% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for June 2013 the Company realized a decrease of sales revenues of 5 % compared to the same period of 2012, including 21% increase of domestic sales and 13% decrease of export sales.

During the past six months Sopharma AD recorded an increase of sales revenues of 0,01%, including 7% increase of domestic sales and 2% decrease of export sales compared to the same period of 2012.

SOPHARMA AD (the “Company”) hereby informs that from 4 July 2013 up to and including 10 July 2013 the Company bought 24738 own shares representing 0.019% of the share capital of the Company, to the total value of BGN 76697.36 on the Bulgarian Stock Exchange. The average price per share was BGN 3.10.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4445506, representing 3.37% of the share capital of the Company.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that Sopharma AD will commence the paying of dividends for 2012 on 29 July 2013 in accordance with a List of Entitled Persons as at 5 July 2013, prepared by the Central Depository.